

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system disorders. The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see **Important Safety Information** including **Boxed Warning** in the full prescribing information available at OLINVYK.com. The company has four investigational drug candidates including TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal clotting in COVID-19 patients.

Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021

Oct 13 2021, 7:00 AM EDT

Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients

Sep 30 2021, 7:00 AM EDT

Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit

Sep 17 2021, 7:00 AM EDT

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
Managing Director
T: 617-430-7576
daniel@lifesciadvisors.com

Management Team

Carrie L. Bourdow

President and Chief Executive Officer

Mark A. Demitrack, MD

Senior Vice President, Chief Medical Officer

Barry Shin

Senior Vice President, Chief Financial Officer

Robert T. Yoder

Senior Vice President, Chief Commercial Officer

Angela Bagley

Vice President, Technical Operations

Linda Wase, MD

Vice President, Medical Affairs

Michael S. Kramer

VP, Scientific Operations, Regulatory and Alliance Management

Katrine Sutton

Vice President, Finance Planning & Analysis

Michael J. Fossler, Pharm. D., Ph. D., F.C.P.

Vice President, Clinical Development and Quantitative Sciences

Todd L. Wandstrat, BS Pharm, RPh, PharmD

Vice President, Health Economics and Medical Sciences

Trevena, Inc.

955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.